Joint effect between regular use of non-steroidal anti-inflammatory drugs, variants in inflammatory genes and risk of lymphoma

Cancer Causes and Control

Volumn 19, Issue 2, 2008, Pages 163-173

  Hoeft, Birgit ^a   Becker, Nikolaus ^a   Deeg, Evelin ^a   Beckmann, Lars ^a   Nieters, Alexandra ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Lymphoma; Non steroidal anti inflammatory drugs (NSAIDs); Single nucleotide polymorphism (SNP)

Indexed keywords

CYCLOOXYGENASE 2; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E SYNTHASE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERMANY; HAPLOTYPES; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; INTRAMOLECULAR OXIDOREDUCTASES; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 38949173290     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-007-9082-9     Document Type: Article

References (82)

1. Jaffé ES, Harris NL, Stein H, Vardiman JWE (2001) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon
2. Levi F, Lucchini F, Negri E, La Vecchia C (2002) Trends in mortality from non-Hodgkin's lymphomas. Leuk Res 26:903-908
3. Cartwright R, Brincker H, Carli PM et al (1999) The rise in incidence of lymphomas in Europe 1985-1992. Eur J Cancer 35:627-633
4. Grulich AE, Vajdic CM (2005) The epidemiology of non-Hodgkin lymphoma. Pathology 37:409-419
5. Gandhi MK, Khanna R (2005) Viruses and lymphoma. Pathology 37:420-433
6. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006) Inflammation and cancer: how hot is the link? Biochem Pharmacol 72:1605-1621
7. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860-867
8. Bosetti C, Gallus S, La VC (2006) Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 17:871-888
9. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH (2003) A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 88:684-688
10. Zhang Y, Holford TR, Leaderer B et al (2004) Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 15:419-428
11. Flick ED, Chan KA, Bracci PM, Holly EA (2006) Use of nonsteroidal antiinflammatory drugs and non-Hodgkin lymphoma: a population-based case-control study. Am J Epidemiol 164:497-504
12. Rosenberg L, Palmer JR, Zauber AG et al (1995) Relation of benzodiazepine use to the risk of selected cancers: breast, large bowel, malignant melanoma, lung, endometrium, ovary, non-Hodgkin's lymphoma, testis, Hodgkin's disease, thyroid, and liver. Am J Epidemiol 141:1153-1160
13. Bernstein L, Ross RK (1992) Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res 52:5510s-5515s
14. Cerhan JR, Anderson KE, Janney CA, Vachon CM, Witzig TE, Habermann TM (2003) Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer 106:784-788
15. Kato I, Koenig KL, Shore RE et al (2002) Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL) (United States). Cancer Causes Control 13:965-974
16. Chang ET, Smedby KE, Hjalgrim H et al (2005) Medication use and risk of non-Hodgkin's lymphoma. Am J Epidemiol 162:965-974
17. Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG (2003) Prescription medications associated with a decreased risk of non-Hodgkin's lymphoma. Am J Epidemiol 157:510-516
18. Holly EA, Lele C, Bracci PM, McGrath MS (1999) Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 150:375-389
19. Holly EA, Bracci PM (2003) Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco. Am J Epidemiol 158:316-327
20. Baker JA, Weiss JR, Czuczman MS, Menezes RJ, Ambrosone CB, Moysich KB (2005) Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer Causes Control 16:301-308
21. Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L (2006) Risk of non-Hodgkin lymphoma and use of non-steroidal anti-inflammatory drugs. Cancer Detect Prev 30:99-101
22. Chang ET, Zheng T, Weir EG et al (2004) Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study. J Natl Cancer Inst 96:305-315
23. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53:1322-1327
24. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E (2004) Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 24:3177-3184
25. Roper RL, Phipps RP (1992) Prostaglandin E2 and cAMP inhibit B lymphocyte activation and simultaneously promote IgE and IgG1 synthesis. J Immunol 149:2984-2991
26. Stein SH, Phipps RP (1992) Anti-class II antibodies potentiate IgG2a production by lipopolysaccharide-stimulated B lymphocytes treated with prostaglandin E2 and IFN-gamma. J Immunol 148:3943-3949
27. IARC (1997) Non-steroidal anti-inflammatory drugs. IARC, Lyon
28. Goodwin JS, Messner RP, Bankhurst AD, Peake GT, Saiki JH, Williams RC Jr (1977) Prostaglandin-producing suppressor cells in Hodgkin's disease. N Engl J Med 297:963-968
29. Cayeux SJ, Beverley PC, Schulz R, Dorken B (1993) Elevated plasma prostaglandin E2 levels found in 14 patients undergoing autologous bone marrow or stem cell transplantation. Bone Marrow Transplant 12:603-608
30. Ladetto M, Vallet S, Trojan A et al (2005) Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 105:4784-4791
31. Hazar B, Ergin M, Seyrek E, Erdogan S, Tuncer I, Hakverdi S (2004) Cyclooxygenase-2 (Cox-2) expression in lymphomas. Leuk Lymphoma 45:1395-1399
32. Li HL, Sun BZ, Ma FC (2004) Expression of COX-2, iNOS, p53 and Ki-67 in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 10:1862-1866
33. Paydas S, Ergin M, Erdogan S, Seydaoglu G (2007) Cyclooxygenase-2 expression in non-Hodgkin's lymphomas. Leuk Lymphoma 48:389-395
34. Wang D, DuBois RN (2006) Prostaglandins and cancer. Gut 55:115-122
35. Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87:2095-2147
36. Dinarello CA, Thompson RC (1991) Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 12:404-410
37. Reznikov LL, Kim SH, Westcott JY et al (2000) IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-gamma. Proc Natl Acad Sci U S A 97:2174-2179
38. Cipollone F, Patrono C (2002) Cyclooxygenase-2 polymorphism: putting a brake on the inflammatory response to vascular injury? Arterioscler Thromb Vasc Biol 22:1516-1518
39. Arend WP (2002) The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 13:323-340
40. Cox DG, Pontes C, Guino E et al (2004) Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer 91:339-343
41. Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F (2004) Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 25:229-235
42. Gallicchio L, McSorley MA, Newschaffer CJ et al (2006) Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 106:1443-1452
43. Sakoda LC, Gao YT, Chen BE et al (2006) Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis 27:1251-1256
44. Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N (2006) Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 15:1126-1131
45. Ulrich CM, Whitton J, Yu JH et al (2005) PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 14:616-619
46. Siezen CL, van Leeuwen AI, Kram NR, Luken ME, van Kranen HJ, Kampman E (2005) Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis 26:449-457
47. Koh WP, Yuan JM, van den Berg D, Lee HP, Yu MC (2004) Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Br J Cancer 90:1760-1764
48. Hedelin M, Chang ET, Wiklund F et al (2007) Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer 120:398-405
49. Lightfoot T, Skibola CF, Adamson P et al (2006) Polymorphisms in the oxidative stress genes, superoxide dismutase, glutathione peroxidase and catalase and risk of non-Hodgin lymphoma. Haematologica 91(9):1222-1227
50. Becker N, Deeg E, Nieters A (2004) Population-based study of lymphoma in Germany: rationale, study design and first results. Leuk Res 28:713-724
51. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70:425-434
52. Lake SL, Lyon H, Tantisira K et al (2003) Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 55:56-65
53. Rothman N, Skibola CF, Wang SS et al (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7:27-38
54. Endres S, Cannon JG, Ghorbani R et al (1989) In vitro production of IL 1 beta, IL 1 alpha, TNF and IL2 in healthy subjects: distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. Eur J Immunol 19:2327-2333
55. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252-266
56. Ferroni P, Martini F, Cardarello CM, Gazzaniga PP, Davi G, Basili S (2003) Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin. Circulation 108:1673-1675
57. Daun JM, Ball RW, Burger HR, Cannon JG (1999) Aspirin-induced increases in soluble IL-1 receptor type II concentrations in vitro and in vivo. J Leukoc Biol 65:863-866
58. Tountas NA, Casini-Raggi V, Yang H et al (1999) Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology 117:806-813
59. Tolusso B, Pietrapertosa D, Morelli A et al (2006) IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics 7:683-695
60. Santtila S, Savinainen K, Hurme M (1998) Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 47:195-198
61. Hurme M, Santtila S (1998) IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 28:2598-2602
62. Vamvakopoulos J, Green C, Metcalfe S (2002) Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. Eur J Immunol 32:2988-2996
63. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539-545
64. Philip M, Rowley DA, Schreiber H (2004) Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 14:433-439
65. Skibola C, Curry JD, Nieters A (2007) Genetic susceptibility to lymphoma. Haematologica 92(7):960-969
66. Zhu H, Liu C (2003) Interleukin-1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway. J Virol 77:5493-5498
67. Witkin SS, Gerber S, Ledger WJ (2002) Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis 34:204-209
68. Ouburg S, Bart AC, Klinkenberg-Knol EC, Mulder CJ, Salvador PA, Morre SA (2005) A candidate gene approach of immune mediators effecting the susceptibility to and severity of upper gastrointestinal tract diseases in relation to Helicobacter pylori and Epstein-Barr virus infections. Eur J Gastroenterol Hepatol 17:1213-1224
69. Kim N, Cho SI, Yim JY et al (2006) The effects of genetic polymorphisms of IL-1 and TNF-A on Helicobacter pylori-induced gastroduodenal diseases in Korea. Helicobacter 11:105-112
70. Nieters A, Kallinowski B, Brennan P et al (2006) Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 131:1879-1886
71. Rollinson S, Levene AP, Mensah FK et al (2003) Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity. Blood 102:1007-1011
72. Wu MS, Shun CT, Huang SP, Cheng AL, Chen LT, Lin JT (2004) Effect of interleukin-1beta and glutathione S-transferase genotypes on the development of gastric mucosa-associated lymphoid tissue lymphoma. Haematologica 89:1015-1017
73. Rothman N, Skibola CF, Wang SS et al (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7:27-38
74. Chang ET, Smedby KE, Hjalgrim H et al (2005) Medication use and risk of non-Hodgkin's lymphoma. Am J Epidemiol 162:965-974
75. Baker JA, Weiss JR, Czuczman MS, Menezes RJ, Ambrosone CB, Moysich KB (2005) Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer Causes Control 16:301-308
76. Franconi F, Brunelleschi S, Steardo L, Cuomo V (2007) Gender differences in drug responses. Pharmacol Res 55:81-95
77. Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749-59
78. Jost PJ, Ruland J (2006) Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences and therapeutic implications. Blood 109(7):2700-2707
79. Kato I, Koenig KL, Baptiste MS et al (2003) History of antibiotic use and risk of non-Hodgkin's lymphoma (NHL). Int J Cancer 107:99-105
80. Doody MM, Linet MS, Glass AG et al (1996) Risks of non-Hodgkin's lymphoma, multiple myeloma, and leukemia associated with common medications. Epidemiology 7:131-139
81. Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG (2003) Prescription medications associated with a decreased risk of non-Hodgkin's lymphoma. Am J Epidemiol 157:510-516
82. Cerhan JR, Wallace RB, Folsom AR et al (1997) Medical history risk factors for non-Hodgkin's lymphoma in older women. J Natl Cancer Inst 89:314-318